Close

Janssen Announces XARELTO Phase 3b Met Primary Endpoint in NVAF Patients

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/23/2024

1. TSLA
2. SPY
3. GM
4. SPOT
5. AMZN
6. SHW
7. AAPL
8. IBM
9. MINN
10. NVDA


Go back to Janssen Announces XARELTO Phase 3b Met Primary Endpoint in NVAF Patients
Johnson & Johnson (NYSE: JNJ) Delayed: 149.56 +0.44 (0.30%)
Previous Close $149.12    52 Week High $126.07 
Open $149.86    52 Week Low $94.28 
Day High $150.49    P/E 31.09 
Day Low $148.20    EPS $4.81 
Volume 10,110,432